Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2002-02-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by bone marrow or peripheral stem cell transplantation in treating patients with relapsed or refractory Hodgkin's lymphoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Temple University
• Treatments: Cisplatin; Cyclophosphamide; Etoposide; Etoposide phosphate

Criteria

DISEASE CHARACTERISTICS:

• Histologically proven stage I-IV Hodgkin's lymphoma

• Must have refractory or relapsed disease, defined by 1 of the following:

• Failure to achieve a complete remission (CR) after 4 courses of conventional-dose front-line chemotherapy

• Disease in second or greater remission

• Patients should be encouraged to undergo transplantation prior to a third salvage regimen

• Patients previously treated with multiple regimens considered on a case-by-case basis

• No chemoresistant disease, defined as active progression with tumor growth greater than 25% by volume during first-line chemotherapy

• Patients who respond to second-line chemotherapy may be eligible

• Stable residual masses after conventional-dose chemotherapy not considered treatment failures

• Active (refractory or relapsed) disease must be proven histologically or documented by gallium nitrate uptake

• Syngeneic marrow transplantation offered to patients with consenting identical twin donor

• No CNS involvement by lymphoma

PATIENT CHARACTERISTICS:

Age:

• 15 to 60 (selected patients up to age 70 may be eligible)

Performance status:

• ECOG 0-2

Life expectancy:

• Not specified

Hematopoietic:

• WBC greater than 4,000/mm^3

• Absolute neutrophil count greater than 2,000/mm^3

• Platelet count greater than 100,000/mm^3

Hepatic:

• Bilirubin less than 2.0 mg/dL

• SGOT and SGPT less than 2 times upper limit of normal

• Albumin greater than 3.0 g/dL

Renal:

• Must meet 1 of the following criteria:

• Creatinine less than 1.8 mg/dL

• Creatinine clearance greater than 60 mL/min

• BUN less than 20 mg/dL

Cardiovascular:

• Left ventricular ejection fraction at least 50%

Pulmonary:

• DLCO, FEV_1, and FVC greater than 50% of predicted OR

• Resting pO_2 greater than 70 mm Hg on room air

Other:

• HIV negative

• No severe neurologic or emotional disorders

• No active infection

• No other disease that would limit life expectancy

• Not pregnant

• Fertile patients must use effective contraception

• Adequate psychosocial support required

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• See Disease Characteristics

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified